Isomorphic Labs, the London-headquartered AI drug discovery company spun out of Google DeepMind, has raised $5bn in a Series C co-led by Greenoaks and Sequoia. The round lands roughly six months after a $2.1bn Series B and takes the company's two most recent raises past $7bn.
Isomorphic was founded by Demis Hassabis, who serves as its chief executive. The company builds on software developed at DeepMind, including AlphaFold, the Nobel Prize-winning model that predicts protein structures, and is applying it to the design of new medicines in cancer and immune disorders.
The Series C was co-led by the two California-based firms. Andreessen Horowitz, Thrive Capital, Temasek and the UK's Sovereign AI fund also took part, alongside Alphabet and two of its investment arms, GV and CapitalG.
That line-up keeps the cap table anchored to Alphabet, which retains exposure through three separate vehicles, while adding a deeper bench of US growth investors and a UK government-backed fund. The participation of the Sovereign AI fund continues its run of cheques into London's most heavily capitalised AI companies.
Terms beyond the headline figure were not disclosed, including the post-money valuation. The Cap Table reported earlier that Isomorphic had been in early talks to raise at a valuation of up to $50bn, almost triple the $17.5bn reportedly attached to its Series B. The company has not confirmed the valuation at which the new round closed.
The pace of the raise stands out even by the standards of this year's AI funding cycle. Moving from a $2.1bn round to a $5bn round inside six months makes it one of the largest private raises by a UK-headquartered company this year.
Use of funds
Isomorphic said the capital will fund further development of IsoDDE, its proprietary drug design engine, and the clinical development infrastructure needed to move its first candidates into human trials. It also plans to build foundational biology models and expand a partner network focused on mechanistic disease biology.
Hassabis said the round would allow the company to accelerate work on its biology models and drive its first therapeutic programmes towards clinical trials. Max Jaderberg, president of Isomorphic, said the company's teams combine machine learning researchers with experienced drug hunters and are producing repeatable scientific advances each week.
What comes next
The step from software to the clinic is the key test for the company's valuation. Until now, Isomorphic's progress has been measured largely through model performance and pharmaceutical partnerships. A first programme entering trials would give investors a clinical milestone against which to price later rounds or a public listing.
For the UK ecosystem, the round adds to a concentration of capital in a small number of London AI companies that are raising multi-billion-dollar rounds from predominantly US investors.
Original source: Tech.eu: https://tech.eu/2026/11/17/sequoia-and-greenoaks-lead-massive-5bn-series-c-funding-round-in-isomorphic-labs/





